Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback